The present invention pertains to a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for use in preventing and/or treating a metabolic disorder and/or muscle atrophy. It also pertains to a method of preventing and/or treating a metabolic disorder and/or muscle atrophy in a subject. It furthermore pertains to use of a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for increasing the level of insulin and/or glucagon in the blood of a subject and the present invention also pertains to a non-therapeutic use or method of a) beta-lactoglobulin orb) a nutritional composition comprising BLG. It also pertains to beta-lactoglobulin (BLG) for use in preventing and/or treating diabetes or prediabetes in a subject. It furthermore pertains to a nutritional composition for use in preventing and/or treating diabetes or prediabetes in a subject.

The present application relates to the administration of plasma, fractions thereof, or mixtures thereof to humans or animals to treat or otherwise improve cognitive impairment disorders, including dementia (e.g., vascular dementia, dementia with Lewy bodies, dementia resulting from Alzheimer's disease, dementia resulting from Parkinson's disease, frontotemporal dementia, and dementia resulting from normal pressure hydrocephalus in humans, and cognitive dysfunction syndrome in companion animals), concussion, and traumatic brain injury. In certain embodiments, the invention comprises a method of treating a cognitive impairment disorder in a human or companion animal subject, said method comprising: administering to said subject one or more cognitive functioning tests to identify a subject suffering from a cognitive impairment disorder; and administering to said subject a therapeutically effective amount of an animal plasma composition; wherein said administration provides an improvement in said subject's results in said one or more cognitive impairment tests.

A method includes: depositing whole blood into at least one separator tube; subjecting the at least one separator tube to a first centrifugal force to cause a combination of the first centrifugal force and separator gel within each separator tube of the at least one separator tube to separate plasma of the whole blood from red and white blood cells of the whole blood within the at least one separator tube, wherein the plasma includes α2M molecules; transferring one or more portions of the plasma from within the at least one separator tube and into at least one isolator; and subjecting the at least one isolator to a second centrifugal force to cause a combination of the second centrifugal force and a filter within each isolator of the at least one isolator to isolate the α2M molecules from other components of the plasma within the at least one isolator.

Provided is a method for treatment of nerve injury and a related disease, comprising: administrating a therapeutically effective amount of a component of plasminogen activation pathway to a subject. Also provided are a medicament, a pharmaceutical composition, a product, and a kit which comprise a component of plasminogen activation pathway for treating the above diseases.

Provided herein are methods of inducing liver regeneration in a subject diagnosed with a liver disorder. The method comprises administering a Plasma Protein Fraction (PPF) to the subject. In certain embodiments, the PPF comprises between 83% and 95% albumin in relation to total proteins. The PPF can be produced from plasma obtained from young individuals, for example, humans 40 years of age or younger.

There is provided herein a composition for boosting the immune system comprising a keratin compound and beta-lactoglobulin (LGB).

The disclosure is in the field of cell therapy, more in particular, stem cell transplantation therapy. The disclosure provides methods and compositions for improving the efficacy of stem cell transplantation therapy by reducing the inflammatory activity of a stem cell transplant. More in particular, the disclosure provides a method for preparing a stem cell transplant with reduced inflammatory activity comprising a step of suspending a composition comprising stem cells in a fibrinogen-depleted plasma and/or in a fibrinogen and C-reactive protein-depleted plasma.

The disclosure is in the field of cell therapy, more in particular, stem cell transplantation therapy. The disclosure provides methods and compositions for improving the efficacy of stem cell transplantation therapy by reducing the inflammatory activity of a stem cell transplant. More in particular, the disclosure provides a method for preparing a stem cell transplant with reduced inflammatory activity comprising a step of suspending a composition comprising stem cells in a fibrinogen-depleted plasma and/or in a fibrinogen and C-reactive protein-depleted plasma.

The present disclosure provides methods of treating plasma protein imbalances or depletion (e.g., plasma protein imbalances or depletion caused by hemorrhagic shock or other clinical conditions), in particular by administering protein compositions derived from plasma or plasma isolates.

The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.